drugset / Trial / NCT00145171
A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
APO303 is a sub-study of patients enrolled in APO401 (the long-term open label safety protocol) and was designed to evaluate adverse events, particularly blood pressure drops when standing up during first dose in patients who have not been exposed to apomorphine before.
Timeline
- Start
- 2001-02
- Primary completion
- —
- Completion
- 2002-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apomorphine | Unknown | 2 mg | Subcutaneous |
| Subject | Apomorphine | Unknown | 10 mg | Subcutaneous |